Drug maker Dr Reddy's Tuesday said it will 'vigorously defend' against allegations that it engaged in conspiracy to fix prices in the US.
In a regulatory filing, the company said it was among the 21 generic pharmaceutical companies and 15 other individual defendants against whom 49 US states, the Commonwealth of Puerto Rico and the District of Columbia had filed a complaint in the US District Court for the District of Connecticut with respect to 116 generic drugs.
"The complaint alleges that Dr Reddy's US subsidiary and the other named defendants engaged in a conspiracy to fix prices and to allocate bids and customers in the United States in the sale of the drugs," the company said.
Reacting to the lawsuit, Dr Reddy's said, "We intend to vigorously defend against these allegations and are in the process of filing our response with the District Court of Connecticut."
It further said, "Currently, we do not foresee any material impact to our operations and consolidated results with respect to this matter."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
